Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cytokinetics ( (CYTK) ) just unveiled an announcement.
On December 12, 2025, Cytokinetics announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorization for MYQORZO® (aficamten) in the EU. This cardiac myosin inhibitor is intended for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, with a final decision expected from the European Commission in early 2026.
The most recent analyst rating on (CYTK) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.
Spark’s Take on CYTK Stock
According to Spark, TipRanks’ AI Analyst, CYTK is a Neutral.
Cytokinetics’ overall stock score reflects significant financial challenges and valuation concerns, offset by promising technical indicators and strategic progress towards drug approvals. The earnings call provided positive guidance, but financial instability remains a key risk.
To see Spark’s full report on CYTK stock, click here.
More about Cytokinetics
Cytokinetics, Incorporated operates in the biopharmaceutical industry, focusing on the development of muscle biology-driven treatments. The company specializes in cardiac and skeletal muscle contractility therapies, targeting diseases such as heart failure and hypertrophic cardiomyopathy.
Average Trading Volume: 2,021,197
Technical Sentiment Signal: Buy
Current Market Cap: $7.37B
For detailed information about CYTK stock, go to TipRanks’ Stock Analysis page.